Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $45.14.

Several research analysts have issued reports on the company. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday, August 9th. Baird R W raised Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an "outperform" rating and a $58.00 price target on the stock. Oppenheimer started coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an "outperform" rating and a $48.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, September 26th.

Dianthus Therapeutics Trading Up 1.5 %

NASDAQ:DNTH traded up $0.44 during midday trading on Thursday, hitting $29.85. 74,543 shares of the stock were exchanged, compared to its average volume of 192,934. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The company has a market capitalization of $876.69 million, a price-to-earnings ratio of -5.31 and a beta of 1.84. The business has a 50-day moving average price of $27.72 and a two-hundred day moving average price of $26.43.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Sell-side analysts forecast that Dianthus Therapeutics will post -2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $236,000. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $265,000. Point72 DIFC Ltd acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $334,000. Finally, Virtu Financial LLC acquired a new position in Dianthus Therapeutics during the 1st quarter worth $390,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.